Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBX7 | O95931 | 1/20 | 0.41 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.41 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 5/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17275789 | 0.84 | CBX7 (0.40) | CBX7CDYL2CDYLCDY1; CDY1BALDH1A1 | |
| SCHEMBL9142318 | 0.82 | LMNA (0.46) | GAALMNA | |
| SCHEMBL9201147 | 0.82 | MAPT (0.43) | HPGDMAPTLMNAPDE4APDE4B | |
| SCHEMBL9203524 | 0.81 | KDM4E (0.44) | ALDH1A1MAPTTSHRTP53BRD4 | |
| SCHEMBL17275671 | 0.80 | ALDH1A1 (0.49) | CBX7CDYL2CDYLCDY1; CDY1BALDH1A1 | |
| SCHEMBL17275717 | 0.80 | CYP3A4 (0.37) | GSK3BPTPN1LMNAMAPK1 | |
| SCHEMBL17275862 | 0.80 | MYC (0.44) | ALDH1A1MAPTTP53 | |
| SCHEMBL16324111 | 0.79 | CBX7 (0.37) | CBX7CDYL2CDYLCDY1; CDY1BALDH1A1 | |
| SCHEMBL16324386 | 0.79 | TP53 (0.42) | CBX7CDYL2CDYLCDY1; CDY1BGAA | |
| SCHEMBL16324200 | 0.78 | CASP3 (0.50) | ALDH1A1HPGDMAPTGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385050-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3145923-B1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-C]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-01-30 | — | — | EP | disclosed |
| US-20190016719-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10112938-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3010914-B1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9616053-B2 | Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3145923-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-20170057960-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3010914-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20160095844-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2015177110-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| WO-2014202493-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | WO | disclosed |
| EP-0497852-B1 | BICYCLO-IMIDAZOLES, PROCESS FOR PRODUCING THEM AND DRUGS CONTAINING THEM | BOEHRINGER MANNHEIM GMBH (DE) | 1995-12-20 | — | — | EP | disclosed |
| EP-0497852-A1 | BICYCLO-IMIDAZOLES, PROCESS FOR PRODUCING THEM AND DRUGS CONTAINING THEM. | BOEHRINGER MANNHEIM GMBH (DE) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006545-A1 | BICYCLO-IMIDAZOLES, PROCESS FOR PRODUCING THEM AND DRUGS CONTAINING THEM | BOEHRINGER MANNHEIM GMBH (DE) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385050-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | TPH1, TPH2, HTR1A | CBX7 2422/4885CDYL2 1450/4885CDYL 1993/4885 |
| US-20190016719-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | TPH1, TPH2, HTR1A | CBX7 2422/4885CDYL2 1450/4885CDYL 1993/4885 |
| US-20170057960-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | TPH1, TPH2, HTR1A | CBX7 2422/4885CDYL2 1450/4885CDYL 1993/4885 |
| US-10112938-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | TPH1, TPH2, HTR1A | CBX7 2422/4885CDYL2 1450/4885CDYL 1993/4885 |
| US-20160095844-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HTR2C, OPRD1, DRD3 | CBX7 3046/4885CDYL2 1406/4885CDYL 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.